EN | DE
Menu hamburgerclose
About us

ZYTOPROTEC AT A GLANCE

Our mission is to make a novel therapeutic approach a reality in PD – an area where clinicians and patients saw disappointingly little innovation in decades.

Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial in 2022.

The Company is lead by a management team that combines extensive expertise in the renal business, in financing and Venture Capital, as well as in nephrology and clinical development.

MANAGEMENT

Key Milestones

2022 Following promising results of an animal study positive preparation for filing of a new "Indikationspatent"

2022 Start of a financing round in the form of a public offer of GmbH-shares and atypical silent partnership interests

2022 Filing of the "double chamber bag patent" in July and positive feedback from the European Patent Office in October (new and inventive)

2021 Transfer of all silent partnerships from Schilling Group to Auxil

2020-2022 Preparation of industrial production of PDprotec®

2019/2022 Letter of Intent with Chinese partner regarding cooperation regarding PDprotec® in China

2019-2022 Product Development of a five-liter-double-chamber-bag of PDprotec®

2019-2021 Successful additional financing through convertible loans, silent partnerships and shareholder loans with a total volume of € 5.8 million

2019-2020 Planning of clinical phase III of PDprotec® in cooperation with Parexel and with positive feedback from the FDA in December 2020 in a so-called pre-IND meeting

May 2019

Issuance of patent for ICOprotec in China

2019

Closing of an EU grant (IMPROVE-PD) with a volume of € 0.5 million

2019

Participation in the EU Horizon 2020 project “IMPROVE-PD"

2019

Issuance of various awards for team members of our Christian-Doppler-Lab (www.cdg.ac.at)

2018

Substantial increase of the scientific adivsory board by adding eight international experts in PD

2017
FDA grants PDprotec® Orphan Drug designation
 
2017
Results of the phase II study on PDprotec®: Excellent data on security and effectiveness
 
2016/2017
Series A2 Funding
 
2016
Laboratory for biomarker research in peritoneal dialysis opened by Zytoprotec
 
2015
Double-blinded, placebo-controlled Phase II study on PDprotec®

2013
Series A Funding

2012
Patent for PDprotec® granted from EPO

2012
Phase I and phase II studies with PDprotec® completed

2011
First financing with private investor

2007
Founding of Zytoprotec
 
 
 

PARTNERS & COOPERATIONS